TY  - GEN
AU  - O'Day,S
AU  - Pavlick,A
AU  - Loquai,C
AU  - Lawson,D
AU  - Gutzmer,R
AU  - Richards,J
AU  - Schadendorf,D
AU  - Thompson,J A
AU  - Gonzalez,R
AU  - Trefzer,U
AU  - Mohr,P
AU  - Ottensmeier,C
AU  - Chao,D
AU  - Zhong,B
AU  - de Boer,C J
AU  - Uhlar,C
AU  - Marshall,D
AU  - Gore,M E
AU  - Lang,Z
AU  - Hait,W
AU  - Ho,P
TI  - A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma
SN  - 1532-1827
PY  - 2011///0916
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Dacarbazine
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Integrin alphaV
KW  - immunology
KW  - Male
KW  - Melanoma
KW  - drug therapy
KW  - Middle Aged
KW  - Skin Neoplasms
KW  - Uveitis
KW  - chemically induced
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/bjc.2011.183
ER  -